Medtronic (NYSE:MDT) will collaborate with Novo Nordisk (NYSE:NVO) to develop a system that integrates insulin dosing data from Novo’s smart insulin pens into Medtronic’s Continuous Glucose Monitoring (CGM) devices.
Novo expects to launch its NovoPen 6 and NovoPen Echo Plus smart insulin pens in 2020, in addition to its disposable prefilled injection solution. The smart insulin pens will be compatible with both Android and iOS devices.
Medtronic will update its CGM systems, including Guardian Connect, to accomodate Novo’s NovoPen products.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.